Wingate Wealth Advisors Inc. Acquires Shares of 1,686 Boston Scientific Co. (NYSE:BSX)

Wingate Wealth Advisors Inc. bought a new position in Boston Scientific Co. (NYSE:BSX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,686 shares of the medical equipment provider’s stock, valued at approximately $151,000.

Other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. bought a new position in shares of Boston Scientific during the third quarter valued at approximately $28,000. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates increased its position in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC purchased a new position in Boston Scientific during the fourth quarter valued at $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific in the third quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 0.3 %

NYSE:BSX opened at $105.33 on Monday. The firm has a market capitalization of $155.24 billion, a price-to-earnings ratio of 84.26, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The business has a fifty day moving average price of $94.88 and a 200-day moving average price of $87.21. Boston Scientific Co. has a one year low of $64.39 and a one year high of $107.17.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Sell-side analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,302 shares of company stock valued at $4,464,725 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BSX. Citigroup raised their price target on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday. Royal Bank of Canada raised their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research note on Thursday. Piper Sandler upped their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. BTIG Research raised their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Raymond James upped their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.